Novartis AG (NYSE:NVS) Shares Bought by Modera Wealth Management LLC

Modera Wealth Management LLC raised its holdings in Novartis AG (NYSE:NVS) by 6.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,776 shares of the company’s stock after purchasing an additional 341 shares during the period. Modera Wealth Management LLC’s holdings in Novartis were worth $562,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Centaurus Financial Inc. raised its position in shares of Novartis by 1.7% during the 3rd quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock valued at $659,000 after acquiring an additional 98 shares in the last quarter. WealthPlan Investment Management LLC raised its position in shares of Novartis by 1.1% during the 3rd quarter. WealthPlan Investment Management LLC now owns 9,494 shares of the company’s stock valued at $1,092,000 after acquiring an additional 100 shares in the last quarter. Bryn Mawr Capital Management LLC raised its position in shares of Novartis by 0.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 12,884 shares of the company’s stock valued at $1,254,000 after acquiring an additional 100 shares in the last quarter. Rothschild Investment LLC raised its position in shares of Novartis by 0.6% during the 4th quarter. Rothschild Investment LLC now owns 16,682 shares of the company’s stock valued at $1,623,000 after acquiring an additional 101 shares in the last quarter. Finally, Avidian Wealth Enterprises LLC raised its position in shares of Novartis by 1.3% during the 3rd quarter. Avidian Wealth Enterprises LLC now owns 7,913 shares of the company’s stock valued at $910,000 after acquiring an additional 102 shares in the last quarter. 13.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVS has been the topic of several research reports. HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Barclays reaffirmed an “underweight” rating on shares of Novartis in a research report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft raised Novartis from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. StockNews.com raised Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 8th. Finally, Morgan Stanley began coverage on Novartis in a research report on Wednesday, February 12th. They issued an “underweight” rating on the stock. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $123.38.

Novartis Trading Up 0.8 %

NYSE:NVS opened at $111.53 on Wednesday. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92. The stock has a market cap of $227.97 billion, a price-to-earnings ratio of 18.97, a PEG ratio of 1.70 and a beta of 0.53. The business has a fifty day moving average of $103.11 and a 200-day moving average of $107.96. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04.

Novartis (NYSE:NVS) last released its quarterly earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Equities analysts predict that Novartis AG will post 8.45 earnings per share for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.